Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.56 |
| ▸ | DDAH1 | O94760 | 4/20 | 0.51 |
| ▸ | NOS2 | P35228 | 6/20 | 0.50 |
| ▸ | NOS1 | P29475 | 6/20 | 0.50 |
| ▸ | NOS3 | P29474 | 5/20 | 0.50 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ARG2 | P78540 | 4/20 | 0.44 |
| ▸ | ARG1 | P05089 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL29778163 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL2411547 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL30361345 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL7928810 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL1791 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL28759066 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL31663499 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL1790 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL6374054 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL29518651 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240130957-A1 | EXTRACTS OF ISOCHRYSIS SPECIES/TISOCHRYSIS SPECIES | SYMRISE AG (DE) | 2024-04-25 | — | — | US | disclosed |
| US-20230293410-A1 | Compositions Comprising Lipophilic Compounds and One or More (Bio)-Alkanediols | SYMRISE AG (DE) | 2023-09-21 | — | — | US | disclosed |
| EP-4025675-A1 | A PERFUME OIL MIXTURE | Symrise AG (DE) | 2022-07-13 | — | — | EP | disclosed |
| EP-3993767-A1 | BLEND OF BEESWAX AND A LACTYLATE ESTER | Symrise AG (DE) | 2022-05-11 | — | — | EP | disclosed |
| EP-3982910-A1 | A COOLING PREPARATION | Symrise AG (DE) | 2022-04-20 | — | — | EP | disclosed |
| EP-3938055-A1 | AN ANTIMICROBIAL MIXTURE | Symrise AG (DE) | 2022-01-19 | — | — | EP | disclosed |
| EP-3911159-A1 | AN ANTIMICROBIAL MIXTURE | Symrise AG (DE) | 2021-11-24 | — | — | EP | disclosed |
| CN-110331156-B | anti-Mical 2 polyclonal antibody and preparation method thereof | 深圳大学 | 2021-10-12 | — | — | CN | disclosed |
| EP-3873622-A1 | A LIQUID AND TRANSPARENT BLEND OF UV FILTERS | Symrise AG (DE) | 2021-09-08 | — | — | EP | disclosed |
| EP-3852713-A1 | COMPOSITIONS COMPRISING ODORLESS 1,2-PENTANEDIOL | Symrise AG (DE) | 2021-07-28 | — | — | EP | disclosed |
| WO-2005074868-A1 | HAIR COSMETIC MATERIAL | MITSUBISHI CHEMICAL CORPORATION (JP) | 2005-08-18 | — | — | WO | disclosed |
| US-20040161405-A9 | Guanidinium transport reagents and conjugates | KAI PHARMACEUTICALS, INC. | 2004-08-19 | — | — | US | disclosed |
| US-20030185788-A1 | Guanidinium transport reagents and conjugates | ROTHBARD JONATHAN B (US) | 2003-10-02 | — | — | US | disclosed |
| WO-2003035862-A2 | REGULATION OF HUMAN ARGINASE SIGNATURE-CONTAINING PROTEIN | BAYER HEALTHCARE AG (DE) | 2003-05-01 | — | — | WO | disclosed |
| US-20030022831-A1 | Compositions and methods for enhancing drug delivery across and into ocular tissues | CELLGATE, INC., A DELAWARE CORPORATION | 2003-01-30 | — | — | US | disclosed |
| EP-0806947-A4 | FORMULATIONS AND METHODS FOR REDUCING SKIN IRRITATION | COSMEDERM TECHNOLOGIES (US) | 1998-10-14 | — | — | EP | disclosed |
| EP-0806947-A1 | FORMULATIONS AND METHODS FOR REDUCING SKIN IRRITATION | COSMEDERM TECHNOLOGIES (US) | 1997-11-19 | — | — | EP | disclosed |
| WO-1996023490-A9 | FORMULATIONS AND METHODS FOR REDUCING SKIN IRRITATION | — | 1996-12-27 | — | — | WO | disclosed |
| US-5554518-A | Stabilized metal-ion-activated L-arginase (L-arginine amidino hydrolase E.C.3.5.3.1) | DEGUSSA AKTIENGESELLCHAFT (DE) | 1996-09-10 | — | — | US | disclosed |
| WO-1996023490-A1 | FORMULATIONS AND METHODS FOR REDUCING SKIN IRRITATION | COSMEDERM TECHNOLOGIES (US) | 1996-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293410-A1 | Compositions Comprising Lipophilic Compounds and One or More (Bio)-Alkanediols | TRPA1, CUTA, OR51E2 | OTC 1040/4885DDAH1 163/4885NOS2 3181/4885 |
| US-20040161405-A9 | Guanidinium transport reagents and conjugates | SLC29A1, SLC29A2, SLC7A1 | OTC 486/4885DDAH1 1497/4885NOS2 3946/4885 |
| US-20030022831-A1 | Compositions and methods for enhancing drug delivery across and into ocular tissues | SLC7A1, ADM2, ARG1 | OTC 172/4885DDAH1 352/4885NOS2 105/4885 |
| US-20030185788-A1 | Guanidinium transport reagents and conjugates | SLC29A1, SLC29A2, SLC7A1 | OTC 486/4885DDAH1 1497/4885NOS2 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.